Back to today’s briefing

Story perspectives

FDA Eases Clozapine Access for Schizophrenia Patients

2/26/2025

30 3

Summary

Story summary

The FDA has lifted the REMS program for clozapine, paving the way for easier access for those battling treatment-resistant schizophrenia. This pivotal decision comes after experts pointed out the program's hindrances during a November 2024 meeting. Although ANC monitoring is still advised, this change promises to enhance patient care and eliminate medication delays.

1 of 1

Story summary

The FDA has lifted the REMS program for clozapine, paving the way for easier access for those battling treatment-resistant schizophrenia. This pivotal decision comes after experts pointed out the program's hindrances during a November 2024 meeting. Although ANC monitoring is still advised, this change promises to enhance patient care and eliminate medication delays.